Man with cystic fibrosis to run London Marathon
A 19-year-old with cystic fibrosis (CF) is aiming to run the London Marathon to raise money for charity and awareness for the ...
Mirage News1d
Triple Combo Drug Approved for Cystic Fibrosis
In two randomised phase 3 studies involving 480 participants aged 12 years and over, ivacaftor/tezacaftor/vanzacaftor was ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...
Arcturus Therapeutics price target lowered to $60 from $63 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the ...
Kalkine Media2d
How Is Sionna Therapeutics (NASDAQ:SION) Positioned to Impact Cystic Fibrosis Care?
Highlights,Sionna Therapeutics has received positive coverage from TD Cowen, Stifel Nicolaus, and Guggenheim.,The stock ...
The Pharma Letter1d
MHRA backing for Alyftrek for cystic fibrosis
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...
Medindia13d
Inhalable Gene Therapy Trialed for Cystic Fibrosis Patients
Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...
Yahoo Finance12d
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...